Denali Therapeutics Inc. Intangible Assets, Net (Excluding Goodwill)
Denali Therapeutics Inc. (DNLI) had Intangible Assets, Net (Excluding Goodwill) of $35.25 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Excluding Goodwill, after Accumulated Amortization
us-gaap:IntangibleAssetsNetExcludingGoodwill · last filed 2026-08-06
- 2026-06-30: Intangible Assets, Net (Excluding Goodwill) $35.25M.
- 2026-03-31: Intangible Assets, Net (Excluding Goodwill) $36.00M.
- 2025-12-31: Intangible Assets, Net (Excluding Goodwill) $0.00.
| Period end | Intangible Assets, Net (Excluding Goodwill) |
|---|---|
| 2026-06-30 | $35.25M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $36.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |